

## Appendix 4E: Preliminary final report for the Year Ended 30 June 2019

This information should be read in conjunction with the attached 2019 Financial Report

Name of Entity: Azure Health Technology Limited

ABN or equivalent company reference	Half-yearly (tick)	Preliminary final (tick)	Financial year ended ('current period')
31 111 082 485		✓	Financial year ended 30 June 2019

### 1. Details of the reporting period and the previous corresponding period:

Current period	1 July 2018 to 30 June 2019
Previous corresponding period	1 July 2017 to 30 June 2018

### 2. RESULTS FOR ANNOUNCEMENT TO THE MARKET

	Year ended 20 June 2019	Year ended 20 June 2018	Changes from previous corresponding period	Changes from previous corresponding period
	\$'000	\$'000	\$'000	%
<b>Total revenue</b>	-	-	-	-
<b>Profit (Loss) from ordinary activities after tax</b>	2,749,752	-	2,749,752	100%
<b>Net Profit attributable to members</b>	2,749,752	-	2,749,752	100%

	30-Jun-19 (cents)	30-Jun-18 (cents)
<b>Net tangible assets per security</b>	(0.13)	(0.21)
<b>Dividends</b>	-	-

### 3. The amount per security and franked amount per security of final and interim dividends or a statement that it is not proposed to pay dividends.

NIL

### 4. The record date for determining entitlements to the dividends (if any).

NA

### 5. A brief explanation of any of the figures in above necessary to enable the figures to be understood.

The Company was placed into voluntary administration on 31 May 2017. The Company subsequently entered a Deed of Company Arrangement ("DOCA") on 7 November 2017 and was then recapitalised. The effectuation of the DOCA occurred on 18 December 2018. According to the DOCA, the company's shares were consolidated on a 1: 382 basis. A further 145 million shares were subsequently issued as part of the DOCA. The above profit included \$3,331,163 Other Income from gain on the debt forgiveness of the secured and unsecured creditors.

The directors are currently seeking opportunities for the Company with a view to enhancing Shareholder value. The aim is to pursue an appropriate business opportunity against which the Company may be further recapitalised and its shares requoted on the Australian Stock Exchange. The principal activity of Azure Health Technology Limited is to research, develop, distribute and market a range of health and therapeutic products and technologies, including innovative drugs, wellbeing supplements and medical devices.

**6. Audit status**

At the date of issue of this report, the consolidated financial report for the year ended 30 June 2019 has been audited.

A handwritten signature in black ink, appearing to be 'G Starr', written over a horizontal line.

---

**G Starr**  
**Company Secretary**  
**26 July 2019**